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Purpose. To report the outcomes after primary intravitreal pegaptanib sodium in patients with diabetic macular edema (DME).
Methods. We conduced a retrospective analysis of eyes with DME treated with primary intravitreal pegaptanib sodium (Macugen)
(intravitreal pegaptanib group). The results were compared with the ones of eyes treated with intravitreal pegaptanib sodium
associated with macular laser photocoagulation (combined treatment group), and the ones of eyes treated with primary macular
laser photocoagulation (macular laser photocoagulation group). Results. For the intravitreal pegaptanib group (13 eyes), we found
signiﬁcant changes in mean best-corrected visual acuity (BCVA) and reductions in mean central macular thickness (CMT) at the
last follow-up visit (P = .0014 and P = .0001). For the macular laser photocoagulation group (15 eyes), we found no statistically
signiﬁcant changes in mean BCVA and CMT at the last follow-up visit (P>. 05). For the combined treatment group (12 eyes),
we found no signiﬁcant changes in mean BCVA at the last follow-up visit (P>. 05) despite signiﬁcant reductions in mean CMT
(P = .0188). Conclusion. Intravitreal pegaptanib treatment alone may be superior to macular laser photocoagulation alone and to
combined intravitreal pegaptanib treatment associated with macular laser photocoagulation in patients with DME.
Copyright © 2009 G. Querques et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Diabetic retinopathy represents the leading cause of blind-
ness in the working age population in the developed
world. In patients with type 1 diabetes, visual loss is more
commonly due to proliferative changes, while in patients
with type 2 diabetes, visual loss is more commonly due to
macular edema [1]. Diabetic macular edema (DME) results
from the exudation and accumulation of extracellular ﬂuid
and proteins in the macula [2] owing to structural changes
in the endothelium of retinal vasculature that lead to the
breakdown of the blood-retina barrier and an increase in
vascular permeability [3].
The gold standard of DME treatment is macular laser
photocoagulation. The beneﬁt of immediate focal photoco-
agulation was demonstrated in the Early Treatment Diabetic
Retinopathy Study (ETDRS) [4]. Laser photocoagulation
reduces moderate visual loss by 50% (from 24% to 12%,
3 years after initiation of treatment), probably by inducing
proliferationofboththeendothelialcellsinretinalcapillaries
and retinal pigment epithelial cells, thereby improving the
eﬃcacies of both inner and outer blood-retinal barriers [5].
However,intheETDRS,thepatientshadonlyminimalvisual
improvement after laser treatment and <3% of patients had
visual improvements of ≥3 lines at 3 years. Moreover, 12%
of eyes developed moderate visual loss at 3 years despite
treatment and 40% of eyes with retinal thickening involving
the central macula had persistent edema at 12 months
[6]. Therefore, a more eﬀective treatment modality is still
needed.
Recently, intravitreal administration of the corticosteroid
triamcinolone acetonide [7–11] and antivascular endothelial
growth factor (VEGF) agents [12–15] have been suggested
as alternative or adjunct treatments for DME. The probable
mechanisms of corticosteroid treatment include increased
expression of retinal endothelial cell tight-junction proteins,
which diminishes vessel leakage by increasing endothelial
barrierproperties,andinhibitoryeﬀectsonVEGFexpression2 Journal of Ophthalmology
[16].VEGFhasbeenimplicatedasanimportantfactorinthe
occurrenceofvascularpermeabilityinoculardiseasessuchas
DME [17, 18].
Pegaptanib sodium (Macugen, Eyetech Pharmaceuticals,
Inc. and Pﬁzer Inc, New York, NY) is a ribonucleic acid
aptamer that targets the VEGF165 isoform that is currently
approved in a number of countries worldwide for the
treatment of neovascular age-related macular degeneration
(AMD) [19]. Phase II trial results of pegaptanib in subjects
with DME have been reported recently, [12] and it is
currently being evaluated in phase III trials for treatment of
DME. Bevacizumab (Avastin, Genentech Inc., San Francisco,
CA) is a full-length humanized antibody that binds to
all isoforms of VEGF and is used successfully in tumor
therapy as a systemic drug [20]. Recent studies have
demonstrated the usefulness of intravitreal injections of
bevacizumab in the reduction of clinically signiﬁcant DME,
macular edema secondary to central retinal vein occlusion,
vascular permeability and ﬁbrovascular proliferation in
retinal neovascularization secondary to proliferative diabetic
retinopathy, and choroidal neovascularization secondary to
AMD [21–26]. Ranibizumab (Lucentis, Genentech, Inc.,
South San Francisco, CA) is a fully humanized monoclonal
antiVEGF antibody binding fragment developed speciﬁcally
for ophthalmic applications. It was designed to bind all
biologically active forms of VEGF and has been eﬀectively
used in the treatment of neovascular AMD [27, 28]. A
recent study has demonstrated the usefulness of intravitreal
injections of ranibizumab in the reduction of clinically
signiﬁcant DME [13].
The purpose of this retrospective study was to report
the functional (best-corrected visual acuity [BCVA]) and
anatomic outcomes resulting from the use of intravitreal
pegaptanib sodium as primary (oﬀ-label) therapy in patients
with DME, and to compare these outcomes with those
obtained with the combination of intravitreal pegaptanib
sodium and macular laser photocoagulation, or with laser
alone.
2.MaterialsandMethods
We conducted a retrospective study of eyes with macular
edemaduetotype2diabetes,treatedwithintravitrealpegap-
tanib sodium, or intravitreal pegaptanib sodium combined
with macular laser photocoagulation, between October 2006
and December 2008, at the Department of Ophthalmology
of the University of Foggia. Institutional review board/ethics
committee approval and patients’ informed consent were
obtained for this study. Before administration of pegaptanib,
the oﬀ-label use of the drug and its potential risks and
beneﬁts were discussed extensively with all patients. We also
reviewed the data from a homogeneous group of patients
(eyes) treated with macular laser photocoagulation alone as
primary therapy for clinically signiﬁcant DME during the
same study period. Excluded were patients with macular
edema secondary to causes other than diabetic maculopathy,
eyes with DME previously treated with intravitreal triamci-
nolone, eyes with macular ischemia (≥1 disc diameters of
capillary closure at the macula on ﬂuorescein angiography),
andthepresenceofanepiretinalmembraneorvitreomacular
traction syndrome. Patients who had any ocular surgery
within 6 months or signiﬁcant media opacities and those
whowerefollowedforlessthan6monthswerealsoexcluded.
Those that had other DME treatments (such as intravitreal
triamcinolone or other antiVEGF therapies) during the
follow-up period were excluded from the analysis. Patients
with a history of uncontrolled hypertension and recent
thromboembolic events were usually not candidates for
pegaptanib treatment.
Each patient underwent a baseline assessment of BCVA
measured at 4m with standard ETDRS charts and an oph-
thalmic examination that included slit-lamp biomicroscopy.
Baseline central retinal characteristics were analyzed through
a dilated pupil performed by a retina specialist by fundus
biomicroscopy, by assessing central leakage on ﬂuorescein
angiography (FA), and by optical coherence tomography
(OCT; OCT3 Stratus, Carl Zeiss, Dublin, CA) utilizing 6
diagonal slow 6-mm radial line scans (software version 4.0).
Theretinalthicknessofthe1-mmcentralretinawasobtained
using the macular thickness map for calculations.
Pegaptanib sodium injections were performed by a
retinal specialist. The product was a preservative-free ready-
to-use sterile solution composed of pegaptanib sodium
dissolved in 10 mM sodium phosphate and 0.9% sodium
chloride buﬀer injection. Presented in glass syringes sealed
with a bromobutyl rubber plunger stopper, pegaptanib
sodium injection had a ﬁxed 27-gauge needle with a
rubber needle shield (tip cap) and a rigid plastic outer
shield. Each eye was prepared with 5% povidone/iodine
solution, draped, and a lid speculum was placed. Eyes were
anesthetized with topical anesthetic, and 0.3mg (0.05ml)
of pegaptanib sodium was injected intravitreally through
the inferotemporal pars plana 3.5 or 4mm posterior to the
limbus, for pseudophakic or phakic patients, respectively.
After the injection, intraocular pressure and retinal artery
perfusion were checked, and patients were instructed to
administer topical antibiotics for 5 days. Standard focal
and/or modiﬁed grid macular laser photocoagulation [4, 5]
was performed alone or in combination with pegaptanib
injection (within the subsequent 3 months).
Patients who underwent pegaptanib injection alone or
in combination with macular laser photocoagulation were
examined at 1 and 6 weeks after each injection and monthly
thereafter. Follow-up was scheduled on the basis of the
pharmacokinetic properties of pegaptanib sodium [29]a n d
was at least 6 weeks from the last injection (when pegaptanib
sodium was presumed to have been cleared from the
vitreous). Patients who underwent macular laser photoco-
agulation alone were examined at 2 weeks and monthly
thereafter.Aftertheinitialtreatment,eachpatientunderwent
assessment of BCVA and ophthalmic examination, which
included slit-lamp biomicroscopy, fundus biomicroscopy,
OCT and FA. FA was performed at the discretion of
the examiner and not at every postinjection evaluation,
which was usually every 6 weeks. Patients underwent repeat
injections when there was a recurrence of DME, deﬁned
as a decrease of BCVA (at least 5 letters) associated withJournal of Ophthalmology 3
an increase of intraretinal ﬂuid due to macular edema on
OCT (at least 50µm) and/or FA after complete or partial
resolution in previous follow-up visits.
Statistical calculations were performed using STATA
10MP for MacOs X and the Epinfo 3.3 software package
(CDC, Atlanta). The analysis of variance (ANOVA) test for
repeated-measures was used to compare the pretreatment
(relative to the day in which the treatment was performed)
and posttreatment (relative to at least 6 weeks from the
last injection) mean BCVA (converted to the logarithm of
the minimum angle of resolution [logMAR]) and the mean
central macular thickness (CMT) of the 3 treatment groups.
SerialcomparisonsofpretreatmentandposttreatmentBCVA
and CMT were performed using the paired t test. The
Spearman coeﬃcient was used in the analysis of correlation
between mean CMT and mean BCVA for each group. The
chosen level of statistical signiﬁcance was P<. 05.
3. Results
A total of 40 eyes of 40 patients with mild-to-severe
nonproliferative diabetic retinopathy, who were treated for
DME at least 6 months before, were included for analysis.
15, 13, and 12 eyes were allocated to the macular laser
photocoagulation alone, intravitreal pegaptanib alone, and
combined treatment (intravitreal pegaptanib and macular
laserphotocoagulation) groups, respectively. Patient baseline
characteristics are summarized in Table 1.
Repeat therapy was provided to 10/13 (76.9%) eyes in
the intravitreal pegaptanib group and in 9/12 (75%) eyes
in the combined treatment group. A total of 27 pegaptanib
injections were administered to the 13 eyes in the intravitreal
pegaptanib group during a mean follow-up period of 6.4
months, and a total of 25 pegaptanib injections were
administered to the 12 eyes in the combined treatment
group, during a mean follow-up period of 11.9 months. A
signiﬁcantly lower number of injections per month were
performed in the combined treatment group compared with
the intravitreal pegaptanib group (P = .0041).
The changes in mean BCVA and CMT for each group are
summarized in Table 2. Comparison of the pretreatment and
posttreatment data (CMT and BCVA) between the 3 treat-
ment groups was performed considering, as pretreatment
values, the data relative to the day in which the treatment
was performed, and as posttreatment values the data relative
to the last follow-up visit. The mean change in BCVA and
CMT of the intravitreal pegaptanib treated group was −0.16
(SD = ±0.15 95% CI =− 0.25,−0.08) and −146.77µm( S D
= ±93.9 95% CI =− 199.4,−94.1). The mean change in
BCVAandCMTofthecombinedtreatmentgroupwas −0.06
(SD = ±0.14 95% CI =− 0.025,−0.13) and −71.67µm
(SD = ±105 95% CI =− 133,10.3). The mean change in
BCVA and CMT for the macular laser photocoagulation
group was 0.03 (SD = ±0.14 95% CI =− 0.04,0.09) and
−19.2µm( S D= ±54.2 95% CI =− 47.5,9.1). For the
macular laser photocoagulation group alone and for the
combinedtreatmentgroup,therewerenosigniﬁcantchanges
in mean BCVA compared with baseline at the last follow-up
visit (P>. 05). For the intravitreal pegaptanib group, there
was a signiﬁcant improvement in mean BCVA compared
with baseline at the last follow-up visit (P = .0014).
For the macular laser photocoagulation group, there
were no statistically signiﬁcant reductions in mean CMT
compared with baseline at the last follow-up visit (P>
.05). For the combined treatment (intravitreal pegaptanib
associated with macular laser photocoagulation) group and
for the intravitreal pegaptanib group there were statistically
signiﬁcant reductions in mean CMT compared with baseline
at the last follow-up visit (P = .0188 and P = .0001, resp.).
For the macular laser photocoagulation group and
the intravitreal pegaptanib group, BCVA at last follow-up
visit showed a modest but statistically signiﬁcant inverse
correlation with CMT (r =− 0.52, P = .0452, and, r =
−0.57, P = .0428, resp.). Conversely, for the combined
treatment group BCVA at the last follow-up visit did not
show a statistically signiﬁcant correlation with CMT (r =
−0.33, P>. 05).
There were no episodes of inﬂammation or severe
decrease of vision immediately after an injection. During
the study, no ocular or systemic adverse events such as
thromboembolicevents(cerebrovascularaccidents,transient
ischemicattacks,myocardialinfarctions,orperipheralvascu-
lar disease) were reported in any of the treatment groups.
4. Discussion
In this retrospective study of patients with DME treated at
ourinstitution,intravitrealpegaptanibwasfoundtoproduce
signiﬁcant improvements in mean BCVA and reductions in
mean CMT from baseline, while with laser photocoagula-
tion alone no signiﬁcant changes in either measure were
apparent. Interestingly, with combined treatment the change
in mean BCVA from baseline to ﬁnal assessment was not
signiﬁcant despite a signiﬁcant reduction in mean CMT
from baseline; moreover, for this group BCVA at the last
follow-up visit did not show a signiﬁcant correlation with
CMT (r =− 0.33, P>. 3025). Therefore, we can infer
that in our study intravitreal pegaptanib treatment alone was
superior to combined intravitreal pegaptanib and macular
laser photocoagulation treatment, and to macular laser
photocoagulation alone, in regard to functional (BCVA),
and both anatomical (CMT) and functional (BCVA) results,
respectively. Based on the ﬁnding that, for the combined
treatment group, despite a good anatomical response a
similar functional result was not so obvious, one can
speculate that macular laser photocoagulation-related sides
eﬀects such as paracentral scotoma, subretinal ﬁbrosis, and
inadvertent foveolar burns [30, 31] could be responsible
for the absence of signiﬁcant changes in mean BCVA
(which was observed in the macular laser photocoagulation
group, as well) despite signiﬁcant reductions in mean CMT,
probably antiVEGF therapy-related (which was not observed
in the macular laser photocoagulation group). Alternatively,
such discrepancy could be due to irreversible degenerative
macular changes in this group (which, owing to the small
sample size, may have represented a signiﬁcant bias). In fact,4 Journal of Ophthalmology
Table 1: Patients’ baseline characteristics. ETDRS: early treatment diabetic retinopathy study, DME: diabetic macular edema, CMT: central
macular thickness, BCVA: best corrected visual acuity.
Pegaptanib Sodium injection group Combined treatment group Macular Laser
Photocoagulation group
Total N◦ of eyes 13 12 15
N◦ of Male patients 8 7 10
Mean age 65,8 ± 6,1 (95% CI = 62.3, 69.2) 62,4 ± 5,5 (95% CI = 59.2, 65.6) 67 ± 8.6 (95% CI = 62.6,
71.6)
Duration of diabetes 13.7yrs (mean) 12,8yrs (mean) 14,9yrs (mean)
Diﬀuse DME 7eyes 7 eyes 9e y e s
Cystoid DME 6eyes 5 eyes 6e y e s
Mean CMT (µm) 509 ± 125,6 (95% CI = 438.6, 579.4) 420,3 ± 116,3 (95% CI = 352.3, 488.2) 335 ± 91,1 (95% CI =
287.4, 382.6)
Mean BCVA (LogMAR) 0,7 ± 0,4 (95% CI = 0.5, 1) 0,3 ± 0,3 (95% CI = 0.1, 0.4) 0.3 ± 0.3 (95% CI = 0.1,
0.4)
Table 2: Changes in mean BCVA and CMT for each group. FU: follow up, BCVA: best corrected visual acuity, CMT: central macular
thickness.
Pegaptanib Sodium injection
group Combined treatment Group Macular Laser Photocoagulation
group
Mean FU (months) 6.41 1 .97 . 3
Total injections 27 25 —
Repeat treatments/
eye 10/13 9/12 —
Mean BCVA
(LogMAR)-Last FU 0.5 ±0.4 (95% CI = 0.2,0.7) 0.3 ±0.2 (95% CI = 0.2 −0.4) 0.3 ±0.3 (95% CI = 0.16,0.45)
Mean CMT-Last FU 362.2 ± 122.9 (95% CI = 293.3,
431.2) 348.6 ±68.5 (95% CI = 308.6,388.6) 315.8 ±87.2 (95% CI = 270.2,361.4)
Mean BCVA
(LogMAR) change
−0.16 ±0.15 (95% CI =
−0.25,−0.08) 0.06 ±0.14 (95% CI =− 0.025,0.13) 0.03 ±0.13 (95% CI =− 0.04,0.09)
Mean CMT change
−146.77 ±93.9 (95% CI =
−199.4,−94.1)
−71.67 ±105. (95% CI =
−133,−10.3)
−19.2 ±54.2 (95% CI =− 47.5,9.1)
there are many variables including atrophy or destruction of
the photoreceptors or retinal pigment epithelium, decreased
photoreceptor function, and altered signal processing within
the macula that may preclude BCVA beneﬁts despite the
presence of measurable alterations in CMT.
The treatments used in this study appeared to be safe. No
ocular or systemic adverse events such as thromboembolic
events were reported in any treatment groups during the
study period.
The Macugen Diabetic Retinopathy Study Group [12]
reported gains in VA of ≥10 letters in 34% and ≥15
letters in 18% of patients with DME after intravitreal
pegaptanib sodium injections in a randomized, double-
masked, multicenter trial with a follow-up of 36 months.
Recently, Chun et al. [13] reported that ranibizumab
therapy has the potential to maintain or improve BCVA
and reduce retinal thickness in patients with DME. In
addition, a trial conducted by the Diabetic Retinopathy
Clinical Research Network demonstrated that the use of
intravitreal bevacizumab in various protocols could reduce
DMEinsomeeyes[26]whileArevaloetal.[25]reportedthat
intravitreal bevacizumab at doses of 1.25 or 2.5mg seemed
to provide stability or improvement in BCVA and CMT in
patients with DME at 6 months.
Considering thekeyroleofVEGF inthepathophysiology
of diabetic retinopathy, VEGF blockade is an attractive
therapeutic approach. It is possible to block all VEGF
isoforms using bevacizumab or ranibizumab. On the other
hand, there is evidence to support selective blockade of the
VEGF165 isoform as a way to reduce the VEGF-mediated
pathologic eﬀect while preserving VEGF-mediated normal
physiologic functions [12]. In the eye, VEGF is necessary and
criticalfornormalneuronalandvesselmaintenanceandper-
formance. VEGF165 is an isoform that is particularly potent
in promoting the increases in ocular neovascularization
and vessel permeability characteristic of diabetic eye disease
[15]. Preclinical studies demonstrate that selective antiVEGF
therapy can inhibit pathological ocular neovascularization
while leaving physiological neovascularization unimpaired
[15]. In contrast, nonselective VEGF blockade has been
shown to impair VEGF-mediated normal physiologic func-
tions, causing regression of normal vasculature as wellJournal of Ophthalmology 5
as reduction of VEGF-mediated neuroprotection [32, 33].
Hence, a nonselective VEGF inhibitor that blocks all VEGF
isoforms could be more deleterious to retinal function over
the long term than a more selective VEGF antagonist that
could spare several of the smaller soluble VEGF isoforms
within the eye.
The speciﬁc inhibition of VEGF165 in our study was
accomplished with pegaptanib sodium, a ribonucleic acid
aptamer. The speciﬁcity, high aﬃnity, and relative lack of
immunogenicity of aptamers compare favorably with both
small and large molecules, including biologic agents such as
antibodies and antibody fragments.
Our study has several limitations in that it is short term,
nonrandomized, uncontrolled, and retrospective, which pre-
clude any estimation of the long-term eﬃcacy or safety of
intravitreal pegaptanib sodium. In addition, apart from the
small number of patients for each group, another limitation
of our study was the lack of standardization of intravitreal
pegaptanib injection and macular laser photocoagulation
timing. The duration of follow-up of at least 6 months
after treatment was also short; however, our ﬁndings provide
useful comparisons with the 6-month results from other
studies.
In conclusion, our ﬁndings demonstrate that selective
inhibition of VEGF165, the VEGF isoform most associ-
ated with both pathological ocular neovascularization and
increased retinal vascular permeability in diabetic retinopa-
thy, may produce a clinically meaningful and statistically
signiﬁcant beneﬁt in the treatment of DME. Moreover, over-
all outcomes suggest that intravitreal pegaptanib treatment
alone may be superior to macular laser photocoagulation
alone and to combined intravitreal pegaptanib treatment
withmacularlaserphotocoagulationinpatientsaﬀectedwith
DME.
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